LEXINGTON, Mass., April 5,
2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of innovative
therapeutics for the treatment of cancer, today announced that
James Dentzer, President and Chief
Executive Officer of Curis, will present a company overview at the
21st Annual Needham Virtual Healthcare Conference. The
presentation will be available for on-demand viewing
starting on Tuesday, April 12,
2022 at 8:45 a.m. ET.
A live webcast of the presentation will be available under
"Events & Presentations" in the Investors section of the
Company's website at www.curis.com. A replay of the webcast will be
available on the Curis website for 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, emavusertib (CA-4948).
Emavusertib is currently undergoing testing in the Phase 1/2
TakeAim Lymphoma trial, in patients with non-Hodgkin's lymphoma
both as a monotherapy and in combination with BTK inhibitor
ibrutinib. Curis is also evaluating emavusertib in the Phase
1/2 TakeAim Leukemia trial in patients with acute myeloid leukemia
and myelodysplastic syndromes, for which it has received Orphan
Drug Designation from the U.S. Food and Drug Administration. In
addition, Curis is engaged in a collaboration with ImmuNext for
development of CI-8993, a monoclonal anti-VISTA antibody, which is
currently undergoing testing in a Phase 1 trial in patients with
solid tumors. Curis is also party to a collaboration with
Genentech, a member of the Roche Group, under which Genentech and
Roche are commercializing Erivedge® for the treatment of
advanced basal cell carcinoma. For more information, visit Curis's
website at www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-21st-annual-needham-virtual-healthcare-conference-301517055.html
SOURCE Curis, Inc.